Rinri’s lead product candidate, Rincell-1, is designed to treat sensorineural hearing loss (SNHL) patients with auditory neuron-related hearing loss by regenerating auditory neurons in the cochlea.
While initially focusing on patients with auditory neuron-related hearing loss, we will continue to consider a broad range of aetiologies and populations to better understand the individuals our therapeutic candidate may treat.